Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib + mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT02575508Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infigratinib in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose and Recommended Phase II Dose at 28 days and 1 more. Status: withdrawn.
02
Drugs
infigratinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02575508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575508.